GlassScriptPhysician profile
Richard Assaf
NPI 1669421392
$16,121.82
in general payments reported to CMS, 2019-2025
30 companies · $1,391 in 2025
The $1,391 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,426 · 2020: $1,550 · 2021: $1,762 · 2022: $1,452 · 2023: $1,642 · 2024: $1,899 · 2025: $1,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,932.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $4,848.05 | 2019-2022 | |
| Abbvie INC. | $1,885.46 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $1,026.32 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $940.40 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Regeneron Healthcare Solutions, INC. | $839.27 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $811.65 | 2019-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $604.25 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $509.16 | 2019-2023 | Siliq, Jublia, Arazlo |
| Leo Pharma INC. | $473.88 | 2019-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $472.12 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $399.30 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $393.30 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $381.58 | 2019-2025 | |
| Almirall LLC | $342.15 | 2019-2022 | |
| Ucb, INC. | $328.67 | 2023-2025 | Bimzelx, Cimzia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $275.20 | 2021-2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.32 | 2022-2024 | Spevigo, Cyltezo |
| Novartis Pharmaceuticals Corporation | $240.89 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $233.86 | 2019-2023 | |
| Dermira, INC. | $159.82 | 2019-2021 | |
| Journey Medical Corporation | $147.83 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $144.73 | 2020-2021 | |
| Organon LLC | $111.85 | 2025 | Vtama, Nexplanon |
| Amgen INC. | $105.83 | 2023-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $63.83 | 2023-2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $40.10 | 2023-2024 | Ycanth |
| Biofrontera INC. | $31.34 | 2020-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Medimetriks Pharmaceuticals, INC. | $22.96 | 2020 | |
| Lnhc, INC | $18.29 | 2025 | Zelsuvmi |
| Mallinckrodt Hospital Products INC. | $17.41 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Assaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.